<DOC>
	<DOCNO>NCT00997386</DOCNO>
	<brief_summary>The purpose study look whether combination lower-dose chemotherapy two chemotherapy ( anti-cancer ) drug , call busulfan melphalan , antibody medication call alemtuzumab ( CampathÂ® ) , prevent rejection donor blood stem cell cell take hold build healthy new blood cell factory transplant . The study also look safety combination drug transplant peripheral blood stem cell healthy relative unrelated donor .</brief_summary>
	<brief_title>Reduced Intensity Allogeneic PBSCT Treat Hematologic Malignancies Hematopoietic Failure States</brief_title>
	<detailed_description>Transplantation relate unrelated allogeneic peripheral blood stem cell ( PBSCs ) administration reduced-intensity regimen busulfan , melphalan alemtuzumab associate satisfactory engraftment acceptable post-transplant non-relapse mortality .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age 50 75 year age 18 49 one risk factor : prior autologous , allogeneic syngeneic HCT ( Hematopoietic cell transplantation ) ; first complete remission first chronic phase ; and/or presence one medical condition would place subject high risk heart kidney disease . Subjects hematologic cancer must receive least one previous course chemotherapy biological therapy . In word , subject enroll trial initial treatment disease . Availability healthy relate unrelated volunteer allogeneic donor . Eligible another study standard care treatment offer high probability cure longterm control subject 's disease . Severe abnormal function organ heart , kidney , liver . Untreated progressive central nervous system involvement disease . Subject pregnant breastfeeding . Performance score 50 : least , require considerable assistance frequent medical care . Positive HIV [ AIDS ] virus Life expectancy le 12 week conventional treatment . For subject capable child , refusal practice birth control study least 12 month PBSCT stop posttransplant immunosuppressive treatment , whichever occurs later .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>lymphoma , leukemia , MDS ( myelodysplastic syndrome )</keyword>
	<keyword>reduced-intensity preparative regimen</keyword>
	<keyword>allogeneic peripheral blood stem cell transplant</keyword>
	<keyword>myelofibrosis myeloproliferative syndrome</keyword>
</DOC>